Introduction
Acute apical abscesses are known for rapid-onset pain and swelling from pulp necrosis. While typically associated with polymicrobial infections, recent research suggests that active herpesvirus infections may also contribute. This randomized, double-blind, placebo-controlled trial aimed to evaluate if valacyclovir, when combined with amoxicillin, can consistently manage pain and how individual patients respond within a larger population.
Methods
This study enrolled 38 emergency patients with moderate to severe pain from acute apical abscesses, randomizing them into 2 treatment groups. Patients in the valacyclovir group (n = 21) received a 1g loading dose of amoxicillin (followed by 500 mg four times daily for 7 days) and a 2g loading dose of valacyclovir (followed by 500 mg twice daily for 3 days). The placebo group (n = 17) received the same amoxicillin regimen along with a placebo. Over a 6-day follow-up, we used daily phone calls to track pain levels with a numeric rating scale and monitor analgesic use. Outcome data were analyzed using the Mann–Whitney and Friedman statistical tests.
Results
The valacyclovir group showed significantly lower mean pain scores on Days 1–3 (P < .05). They experienced a faster reduction in moderate/severe pain and a higher rate of reporting no pain (numeric rating scale= 0) throughout the study. Analgesic use dropped sharply in the valacyclovir group, with only 28.6% using analgesics on Day 1 compared to 82.4% in the placebo group. This consistently lower usage was maintained through Day 6.
Conclusion
Valacyclovir shows promise as an adjunctive therapy for early pain relief in patients with acute apical abscesses.
扫码关注我们
求助内容:
应助结果提醒方式:
